Clinical and Genetic Aspects of Coagulopathies

Koller, Fritz
April 1965
Annals of Internal Medicine;Apr65, Vol. 62 Issue 4, p744
Academic Journal
Focuses on the clinical and genetic aspects of blood coagulation disorders. Deficiency of clotting factors in hereditary and acquired coagulopathies; Hemophilia in royal families in Europe; Potentiation of anticoagulant effect of dicoumarol derivative by phenylbutazone.


Related Articles

  • Coexistence of lupus anticoagulant and acquired haemophilia in a patient with monoclonal gammopathy of unknown significance. Taher, A.; Abiad, R.; Uthman, I. // Lupus;2003, Vol. 12 Issue 11, p854 

    Acquired haemophilia or factor VIII (FVIII) deficiency,caused by FVIII inhibitor antibodies, is avery rare condition that commonly results in severe haemorrhagic complications. We report a case of acquired haemophilia presenting with a left calf nontraumatic haematoma. The patient was also found...

  • Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII? Kessler, Craig // Intensive Care Medicine;Oct2002 Supplement 2, Vol. 28, pS228 

    Recombinant activated factor VII (rFVIIa, 'NovoSeven') is indicated for the treatment of bleeding in patients with haemophilia and inhibitors to factors VIII or IX. However, by virtue of its ability to promote thrombin generation on the platelet surface rFVIIa may also be effective in...

  • Coagulation disorders and anti-coagulants. Bansal, Pranav; Jain, gaurav // Anaesthesia, Pain & Intensive Care;Oct-Dec2011, Vol. 15 Issue 3, p198 

    A quiz concerning blood coagulation disorders and anti-coagulants in the management of patients with neuraxial block is presented.

  • A chamber of hope for hemophilia. Pipe, Steven W.; Kaufman, Randal J. // Nature Biotechnology;Mar2000, Vol. 18 Issue 3, p264 

    Focuses on the blood coagulation disorder hemophilia. Cause of the disease; Role of genetic engineering in treating hemophiliacs; Side effects of the treatment; Method devised by Ton-That and coworkers to overcome the obstacles.

  • Hemophilia bypassed. DeWitt, Natalie // Nature Biotechnology;Mar2000, Vol. 18 Issue 3, p251 

    Focuses on the blood coagulation disorder hemophilia, caused by deficiencies or defects of blood coagulation factors. Side effects of therapies based on replacement of defective plasma proteins; Limitations of using recombinant Factor VIIa in the treatment of the disease; Development of an...

  • Further assessment for factor VIII meds recommended by PRAC.  // Reactions Weekly;Nov2014, Vol. 1528 Issue 1, p5 

    The article reports that according to the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency, patients with previously untreated haemophilia may be at greater risk of developing inhibitors if treated with the second-generation factor VIII products.

  • Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Björkman, S.; Berntorp, E.; Björkman, S // Clinical Pharmacokinetics;2001, Vol. 40 Issue 11, p815 

    Haemophilia is a recessively inherited coagulation disorder, in which an X-chromosome mutation causes a deficiency of either coagulation factor VIII (FVIII) in haemophilia A, or factor IX (FIX) in haemophilia B. Intravenous administration of FVIII or FIX can be used to control a bleeding...

  • The laboratory diagnosis of the carrier state for classic hemophilia. Ratnoff, Oscar D.; Jones, Paul K.; Ratnoff, O D; Jones, P K // Annals of Internal Medicine;May77, Vol. 86 Issue 5, p521 

    Estimation of the titer of procoagulant antihemophilic factor (AHF) and the concentration of AHF-like antigens, as detected by heterologous antiserum, provides a method for diagnosis of the carrier state of classic hemophilia. Among 87 obligate carriers, 82, or 94%, could be identified as...

  • Inflammation and Coagulation: Implications for the Septic Patient. Dellinger, R. Phillip // Clinical Infectious Diseases;5/15/2003, Vol. 36 Issue 10, p1259 

    Sepsis with acute organ dysfunction (severe sepsis) is common, frequently fatal, and associated with a significant national health/economic burden. In addition to standard care, investigators have focused on interrupting the inflammatory and anti-inflammatory cascade associated with this...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics